Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE9A | O76083 | 3/20 | 0.60 |
| ▸ | PDE1A | P54750 | 2/20 | 0.60 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.60 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.60 |
| ▸ | PDE5A | O76074 | 1/20 | 0.60 |
| ▸ | DRD1 | P21728 | 2/20 | 0.45 |
| ▸ | DRD5 | P21918 | 2/20 | 0.45 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
| ▸ | ADCY10 | Q96PN6 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | RUNX1 | Q01196 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.37 |
| ▸ | OXTR | P30559 | 1/20 | 0.37 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.37 |
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30947394 | 1.00 | PDE9A (0.60) | PDE9APDE1APDE1BPDE1CPDE5A | |
| SCHEMBL6692513 | 0.85 | PDE9A (0.63) | PDE9APDE1APDE1BPDE1CPDE5A | |
| Hydrochloric Acid SCHEMBL6758970 | 0.84 | PDE9A (0.62) | PDE9APDE1APDE1BPDE1CPDE5A | |
| SCHEMBL6366070 | 0.82 | PDE9A (0.44) | PDE9APDE1APDE1BPDE1CPDE5A | |
| SCHEMBL30947390 | 0.81 | PDE9A (0.77) | PDE9APDE1APDE1BPDE1CPDE5A | |
| SCHEMBL5064284 | 0.81 | PDE9A (0.77) | PDE9APDE1APDE1BPDE1CPDE5A | |
| SCHEMBL3493363 | 0.81 | PDE9A (0.55) | PDE9APDE1APDE1BPDE1CDRD2 | |
| SCHEMBL6692504 | 0.81 | PDE9A (0.64) | PDE9APDE1APDE1BPDE1CPDE5A | |
| Hydrochloric Acid SCHEMBL6756650 | 0.81 | PDE9A (0.76) | PDE9APDE1APDE1BPDE1CPDE5A | |
| SCHEMBL5065550 | 0.81 | PDE9A (0.64) | PDE9APDE1APDE1BPDE1CPDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004096811-A1 | PDE9 INHIBITORS FOR TREATING TYPE 2 DIABETES, METABOKIC SYNDROME, AND CARDIOVASCULAR DISEASE | PFIZER PRODUCTS INC. (US) | 2004-11-11 | — | — | WO | claimed |
| US-20040220186-A1 | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease | PFIZER INC. | 2004-11-04 | — | — | US | claimed |
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES INC (US) | 2025-11-27 | — | — | US | disclosed |
| US-20210386743-A1 | USE OF PDE9 INHIBITORS FOR TREATMENT | THE JOHNS HOPKINS UNIVERSTY | 2021-12-16 | — | — | US | disclosed |
| US-20080282364-A1 | Phosphodiesterase 9 Inhibition as Treatment for Obesity-Related Conditions | BLACK SHAWN C | 2008-11-13 | — | — | US | disclosed |
| EP-1686998-A1 | PHOSPHODIESTERASE 9 INHIBITION AS TREATMENT FOR OBESITY-RELATED CONDITIONS | Pfizer Products Inc. (US) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005041972-A1 | PHOSPHODIESTERASE 9 INHIBITION AS TREATMENT FOR OBESITY-RELATED CONDITIONS | PFIZER PRODUCTS INC. (US) | 2005-05-12 | — | — | WO | disclosed |
| US-20040220186-A1 | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease | PFIZER INC. | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | PDE9A, PDE3A, PDE2A | PDE9A 1/4885PDE1A 30/4885PDE1B 25/4885 |
| US-20040220186-A1 | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease | PDE9A, PDE2A, PDE12 | PDE9A 1/4885PDE1A 12/4885PDE1B 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.